{"id":1838,"date":"2018-04-11T10:37:45","date_gmt":"2018-04-11T02:37:45","guid":{"rendered":"http:\/\/www.sugonedu.com\/?p=1838"},"modified":"2018-04-12T11:38:58","modified_gmt":"2018-04-12T03:38:58","slug":"%e8%82%bf%e7%98%a4%e7%b2%be%e5%87%86%e5%8c%bb%e5%ad%a6%e5%a4%a7%e6%95%b0%e6%8d%ae%e6%8a%80%e6%9c%af-2","status":"publish","type":"post","link":"http:\/\/112.123.118.11:9997\/?p=1838","title":{"rendered":"\u80bf\u7624\u7cbe\u51c6\u533b\u5b66\u5927\u6570\u636e\u6280\u672f"},"content":{"rendered":"
\u80bf\u7624\u7cbe\u51c6\u533b\u5b66\u5927\u6570\u636e\u6280\u672f<\/div>\n
\u7275\u5934\u5355\u4f4d:<\/span>\u4e2d\u79d1\u9662\u8ba1\u7b97\u6280\u672f\u7814\u7a76\u6240<\/div>\n
\n\u4e2d\u79d1\u9662\u8ba1\u7b97\u6280\u672f\u7814\u7a76\u6240\u5728\u4f53\u7cfb\u7ed3\u6784\u3001\u5927\u6570\u636e\u3001\u4e91\u8ba1\u7b97\u3001\u4eba\u5de5\u667a\u80fd\u7b49\u65b9\u5411\u56fd\u9645\u9886\u5148\u3002\u89c4\u5212\u548c\u5b9e\u65bd\u8fc7\u591a\u4e2a\u56fd\u5bb6\u7ea7\u7684\u91cd\u5927\u79d1\u7814\u9879\u76ee\uff0c\u5177\u6709\u8de8\u5b66\u79d1\u7684\u77e5\u8bc6\u50a8\u5907\uff0c\u6267\u884c\u8fc7\u5728\u201c973\u201d\u3001\u81ea\u7136\u79d1\u5b66\u57fa\u91d1\u91cd\u5927\u4eea\u5668\u7b49\u751f\u547d\u79d1\u5b66\u548c\u4fe1\u606f\u5b66\u4ea4\u53c9\u7684\u79d1\u7814\u4efb\u52a1\u3002\n<\/div>\n
\n

\u5355\u4f4d\uff1a\u4e2d\u79d1\u9662\u8ba1\u7b97\u6280\u672f\u7814\u7a76\u6240<\/strong><\/p>\n

    \n
  1. \u6280\u672f\u7b80\u4ecb<\/strong><\/li>\n<\/ol>\n

    \u7cbe\u51c6\u533b\u5b66\u662f\u751f\u7269\u6280\u672f\u548c\u4fe1\u606f\u6280\u672f\u5728\u4e34\u5e8a\u5b9e\u8df5\u7684\u4ea4\u6c47\u3001\u878d\u5408\u3001\u5e94\u7528\uff0c\u662f\u533b\u5b66\u79d1\u6280\u53d1\u5c55\u7684\u524d\u6cbf\u65b9\u5411\u3002\u5f53\u524d\u9636\u6bb5\u7684\u7cbe\u51c6\u533b\u5b66\u662f\u4ee5\u7ec4\u5b66\u7814\u7a76\u4e3a\u6838\u5fc3\u3002\u57fa\u56e0\u7ec4\u5b66\u6570\u636e\u91cf\u5de8\u5927\uff0c\u6316\u636e\u57fa\u56e0\u6570\u636e\u548c\u8868\u578b\u6570\u636e\u5173\u7cfb\u7b97\u6cd5\u590d\u6742\uff0c\u6211\u4eec\u8bbe\u8ba1\u4e86\u9762\u5411\u751f\u547d\u79d1\u5b66\u5927\u6570\u636e\u5904\u7406\u7684\u8ba1\u7b97\u673a\u7cfb\u7edf\uff08\u5904\u7406DNA\uff0cRNA\uff0cMeta\uff0c\u56fe\u50cf\uff09\uff0c\u5229\u7528\u5343\u4e07\u4ebf\u6b21\u7684\u8ba1\u7b97\u80fd\u529b\u3001PB\u7ea7\u7684\u6570\u636e\u5b58\u50a8\u5bb9\u91cf\u548c\u53ef\u9760\u9ad8\u6548\u7684\u7b97\u6cd5\u6d41\u7a0b\u4e3a\u7528\u6237\u63d0\u4f9b\u4e00\u7ad9\u5f0f\u7684\u89e3\u51b3\u65b9\u6848\uff0c\u8ba9\u884c\u4e1a\u7528\u6237\u4ee5\u53cb\u597d\u7684\u65b9\u5f0f\u5206\u6790\u7ec4\u5b66\u6570\u636e\uff0c\u4ece\u800c\u63a8\u52a8\u884c\u4e1a\u7684\u53d1\u5c55\u3002<\/p>\n

      \n
    1. \u5e94\u7528\u6210\u679c<\/strong><\/li>\n<\/ol>\n

      \u5728\u9762\u5411\u751f\u547d\u79d1\u5b66\u5927\u6570\u636e\u5904\u7406\u7684\u8ba1\u7b97\u673a\u7cfb\u7edf\u4e0a\u63d0\u4f9b\u5982\u4e0b\u670d\u52a1\uff1a<\/p>\n

      \u88681 \u5e94\u7528\u670d\u52a1\u5217\u8868<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
      \u670d\u52a1\u540d\u79f0<\/strong><\/td>\n\u610f\u4e49<\/strong><\/td>\n<\/tr>\n
      \u764c\u53d8\u7b5b\u67e5<\/td>\n\u57fa\u4e8e\u4e34\u5e8a\u80bf\u7624\u60a3\u8005\u5168\u7a0b\u7ba1\u7406\u7406\u5ff5\uff0c\u5bf9\u5f02\u5e38\u589e\u751f\u7ec4\u7ec7\u8fdb\u884c\u764c\u53d8\u7b5b\u67e5\uff0c\u4ece\u5206\u5b50\u5c42\u9762\u4e0a\u4e86\u89e3\u5f02\u5e38\u589e\u751f\u7ec4\u7ec7\u662f\u5426\u764c\u53d8\uff0c\u505a\u5230\u63d0\u524d\u9884\u9632\uff0c\u6392\u67e5\u80bf\u7624\uff0c\u9632\u6b62\u80bf\u7624\u8fdb\u4e00\u6b65\u53d1\u751f\uff0c\u6076\u6027\u8f6c\u5316\u7b49\uff1b\u5bf9\u4e8e\u9633\u6027\u7ed3\u679c\u7684\u60a3\u8005\uff0c\u53ef\u4ee5\u4e86\u89e3\u80bf\u7624\u5206\u5b50\u8fdb\u5316\u8fc7\u7a0b\uff0c\u66f4\u6709\u5229\u4e8e\u540e\u671f\u764c\u75c7\u6cbb\u7597\u3002<\/td>\n<\/tr>\n
      \u80bf\u7624\u7cbe\u51c6\u7528\u836f\u65b9\u6848<\/td>\n\u5168\u5916\u663e\u5b50\u6d4b\u5e8f\u66f4\u52a0\u5168\u9762\u3001\u6df1\u523b\u3001\u51c6\u786e\u7684\u53cd\u6620\u60a3\u8005\u80bf\u7624\u4f53\u7ec6\u80de\u53d8\u5f02\u7684\u7279\u5f81\uff0c\u5e2e\u52a9\u627e\u5230\u80bf\u7624\u8fdb\u5c55\u53d1\u751f\u7684\u4e3b\u8981\u81f4\u75c5\u7a81\u53d8\uff0c\u4e3a\u60a3\u8005\u4e34\u5e8a\u7cbe\u51c6\u7528\u836f\u6cbb\u7597\u3001\u5206\u5b50\u5206\u578b\u53ca\u7597\u6548\u590d\u53d1\u76d1\u63a7\u63d0\u4f9b\u6700\u4f73\u53c2\u8003\uff0c\u5bf9\u63d0\u9ad8\u80bf\u7624\u60a3\u8005\u603b\u751f\u5b58\u671f\uff0c\u6539\u5584\u80bf\u7624\u60a3\u8005\u5728\u6cbb\u7597\u8fc7\u7a0b\u751f\u6d3b\u8d28\u91cf\u63d0\u4f9b\u5de8\u5927\u4ef7\u503c\u3002<\/td>\n<\/tr>\n
      \u4e73\u817a\u764c\u5316\u7597\u8f85\u52a9\u65b9\u6848<\/td>\n\u5224\u65ad\u54ea\u4e9b\u60a3\u8005\u53ef\u4ee5\u91c7\u53d6\u8be5\u7d2b\u6749\u9187\u6cbb\u7597\u65b9\u6848\uff0c\u54ea\u4e9b\u60a3\u8005\u4e0d\u80fd\u91c7\u53d6\u8be5\u6cbb\u7597\u65b9\u6848\u3002<\/td>\n<\/tr>\n
      \u5316\u7597\u836f\u7269\u7b5b\u67e5\u65b9\u6848<\/td>\n\u4e3a\u60a3\u8005\u627e\u5230\u66f4\u5408\u9002\u7684\u5316\u7597\u836f\uff0c\u53ef\u4ee5\u660e\u663e\u63d0\u9ad8\u60a3\u8005\u603b\u751f\u5b58\u671f\uff0c\u540c\u65f6\u6700\u5927\u7a0b\u5ea6\u51cf\u5c11\u5316\u7597\u836f\u7269\u526f\u4f5c\u7528\u5bf9\u60a3\u8005\u7684\u4f24\u5bb3\uff0c\u63d0\u9ad8\u60a3\u8005\u751f\u6d3b\u8d28\u91cf\u3002\u51cf\u8f7b\u5316\u7597\u4f5c\u7528\u526f\u4f5c\u7528\uff0c\u5bf9\u80bf\u7624\u60a3\u8005\u6709\u7279\u522b\u5927\u610f\u4e49\u3002<\/td>\n<\/tr>\n
      \u514d\u75ab\u836f\u7269\u9002\u7528\u6027\u5224\u65ad\u65b9\u6848<\/td>\n\u6839\u636e\u80bf\u7624\u4f53\u7ec6\u80de\u53d8\u5f02\uff08\u53d8\u5f02\u8d1f\u62c5\u3001\u5fae\u536b\u661fDNA\u4e0d\u7a33\u5b9a\uff0cMMR\u7b49\uff09\uff0c\u5e76\u7ed3\u5408\u80bf\u7624\u5185\u6d78\u6da6\u6027\u6dcb\u5df4\u7ec6\u80de\u7684\u542b\u91cf\uff0c\u5224\u65ad\u5f53\u524d\u75c5\u4eba\u662f\u5426\u9002\u7528\u4e8e\u9488\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9Pd-1\u5206\u5b50\u6291\u5236\u7684\u514d\u75ab\u836f\u7269\u6cbb\u7597\u3002<\/td>\n<\/tr>\n
      Car-T\u65b9\u6848\u7684\u5316\u7597\u8f85\u52a9\u65b9\u6848<\/td>\n\u5224\u65ad\u60a3\u8005\u4f53\u5185\u80bf\u7624\u7684\u6076\u6027\u7a0b\u5ea6\uff0c\u6307\u5bfc\u533b\u751f\u91c7\u53d6\u9002\u5f53\u6cbb\u7597\u65b9\u6848\uff1a\u4e73\u817a\u764c\u9884\u540e\u3001\u80ba\u764c\u9884\u540e\u3002<\/td>\n<\/tr>\n
      \u5355\u57fa\u56e0\u9057\u4f20\u75c5\u7b5b\u67e5\u65b9\u6848<\/td>\n\u5355\u57fa\u56e0\u9057\u4f20\u75c5\u57fa\u56e0\u68c0\u6d4b\u53ef\u8f85\u52a9\u4e34\u5e8a\u4e3a\u7591\u4f3c\u60a3\u8005\u7684\u8bca\u65ad\u548c\u6cbb\u7597\u63d0\u4f9b\u4f9d\u636e\uff1b\u4e3a\u6709\u9057\u4f20\u75c5\u53f2\u7684\u5bb6\u5ead\u63d0\u4f9b\u751f\u80b2\u6307\u5bfc\uff0c\u505a\u5230\u4f18\u751f\u4f18\u80b2\uff1b\u5bf9\u65e0\u4e34\u5e8a\u75c7\u72b6\u8868\u73b0\u8005\uff0c\u901a\u8fc7\u57fa\u56e0\u68c0\u6d4b\uff0c\u53ef\u4ee5\u4e86\u89e3\u81ea\u8eab\u81f4\u75c5\u57fa\u56e0\u643a\u5e26\u60c5\u51b5\uff0c\u505a\u5230\u53ca\u65e9\u5e72\u9884\u3002\u901a\u8fc7\u8fd9\u9879\u57fa\u56e0\u68c0\u6d4b\uff0c\u5bf9\u63d0\u9ad8\u4eba\u53e3\u7d20\u8d28\u5177\u6709\u91cd\u8981\u7684\u73b0\u5b9e\u610f\u4e49\u3002<\/td>\n<\/tr>\n
      \u80bf\u7624\u9057\u4f20\u98ce\u9669\u8bc4\u4f30\u65b9\u6848<\/td>\n\u8bc4\u4f30\u662f\u5426\u5b58\u5728\u80bf\u7624\u9057\u4f20\u98ce\u9669\uff1b\u505a\u5230\u65e9\u9884\u9632\uff0c\u65e9\u5e72\u9884\uff0c\u65e9\u53d1\u73b0\uff0c\u65e9\u6cbb\u7597\uff1b\u534f\u52a9\u533b\u751f\u4e3a\u53d7\u68c0\u8005\u5b9a\u5236\u6700\u9002\u5408\u7684\u80bf\u7624\u9884\u9632\u65b9\u6848\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      \u88682\u00a0\u4f1a\u8986\u76d6FDA\/CFAD \u6279\u51c6\u6216\u4e34\u5e8a\u4e8c\u671f\u4ee5\u4e0a\u7684\u836f\u7269<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
      Afatinib
      \n\u963f\u6cd5\u66ff\u5c3c<\/td>\n      		Dabrafenib
      \n\u8fbe\u62c9\u83f2\u5c3c<\/td>\n      		Necitumumab
      \n\u8010\u6614\u59a5\u73e0\u5355\u6297<\/td>\n      		Romidepsin
      \n\u7f57\u7c73\u5730\u8f9b<\/td>\n      		Aflibercept
      \n\u963f\u67cf\u897f\u666e<\/td>\n      		Daratumumab<\/td>\nNintedanib
      \n\u5c3c\u8fbe\u5c3c\u5e03<\/td>\n      		Ruxolitinib
      \n\u9c81\u7d22\u66ff\u5c3c<\/td>\n<\/tr>\n
      Aldesleukin
      \n\u91cd\u7ec4\u4eba\u767d\u4ecb\u7d20-2<\/td>\n      		Dasatinib
      \n\u8fbe\u6c99\u66ff\u5c3c<\/td>\n      		Nilotinib
      \n\u5c3c\u7f57\u66ff\u5c3c<\/td>\n      		Siltuximab
      \n\u53f8\u59a5\u6614\u5355\u6297<\/td>\n      		Alectinib
      \n\u963f\u96f7\u66ff\u5c3c<\/td>\n      		Denosumab
      \n\u72c4\u8bfa\u585e\u9ea6<\/td>\n      		Nimotuzumab
      \n\u5c3c\u59a5\u73e0\u5355\u6297<\/td>\n      		Sonidegib
      \n\u7d22\u5c3c\u5f97\u5409<\/td>\n<\/tr>\n
      Alemtuzumab
      \n\u963f\u4f26\u5355\u6297\u3001\u963f\u83b1\u73e0\u5355\u6297<\/td>\n      		Dinutuximab
      \n\u5730\u52aa\u56fe\u5e0c\u5355\u6297<\/td>\n      		Nivolumab
      \n\u7eb3\u6b66\u5355\u6297<\/td>\n      		Sorafenib
      \n\u7d22\u62c9\u83f2\u5c3c<\/td>\n      		Atezolizumab<\/td>\nElotuzumab
      \n\u57c3\u7f57\u59a5\u73e0\u5355\u6297<\/td>\n      		Obinutuzumab
      \n\u5965\u6ee8\u5c24\u59a5\u73e0\u5355\u6297<\/td>\n      		Sunitinib
      \n\u8212\u5c3c\u66ff\u5c3c<\/td>\n<\/tr>\n
      Axitinib
      \n\u963f\u897f\u66ff\u5c3c<\/td>\n      		Emtansine<\/td>\nOfatumumab
      \n\u5965\u6cd5\u6728\u5355\u6297<\/td>\n      		Synribo
      \n\u9ad8\u4e09\u5c16\u6749\u916f\u78b1<\/td>\n      		Belinostat
      \n\u8d1d\u5229\u53f8\u4ed6<\/td>\n      		Erlotinib
      \n\u5384\u6d1b\u66ff\u5c3c<\/td>\n      		Olaparib
      \n\u5965\u62c9\u5e15\u5c3c<\/td>\n      		Temsirolimus
      \n\u66ff\u897f\u7f57\u83ab\u53f8<\/td>\n<\/tr>\n
      Blinatumomab<\/td>\nGefitinib
      \n\u5409\u975e\u66ff\u5c3c<\/td>\n      		Palbociclib
      \n\u5e15\u535a\u897f\u5c3c<\/td>\n      		Trametinib
      \n\u66f2\u7f8e\u66ff\u5c3c<\/td>\n      		Bortezomib
      \n\u787c\u66ff\u4f50\u7c73<\/td>\n      		Ibritumomab
      \n\u66ff\u4f0a\u83ab\u5355\u6297<\/td>\n      		Panitumumab
      \n\u5e15\u5c3c\u5355\u6297<\/td>\n      		Trastuzumab
      \n\u66f2\u59a5\u73e0\u5355\u6297<\/td>\n<\/tr>\n
      Bosutinib
      \n\u535a\u8212\u66ff\u5c3c<\/td>\n      		Ibrutinib
      \n\u4f9d\u9c81\u66ff\u5c3c<\/td>\n      		Panobinostat
      \n\u5e15\u6bd4\u53f8\u4ed6<\/td>\n      		Vandetanib
      \n\u51e1\u5fb7\u4ed6\u5c3c<\/td>\n      		Brentuximab
      \n\u672c\u59a5\u6614\u5355\u6297<\/td>\n      		Icotinib
      \n\u57c3\u514b\u66ff\u5c3c<\/td>\n      		Pazopanib
      \n\u5e15\u5511\u5e15\u5c3c<\/td>\n      		Vemurafenib
      \n\u5a01\u7f57\u975e\u5c3c<\/td>\n<\/tr>\n
      Cabozantinib
      \n\u5361\u535a\u66ff\u5c3c<\/td>\n      		Idelalisib<\/td>\nPembrolizumab
      \n\u5e15\u59c6\u5355\u6297<\/td>\n      		Venetoclax<\/td>\nCarfilzomib
      \n\u5361\u975e\u4f50\u7c73<\/td>\n      		Imatinib
      \n\u4f0a\u9a6c\u66ff\u5c3c<\/td>\n      		Pertuzumab
      \n\u5e15\u59a5\u73e0\u5355\u6297<\/td>\n      		Vismodegib
      \n\u7ef4\u83ab\u5fb7\u5409<\/td>\n<\/tr>\n
      Ceritinib
      \n\u8272\u745e\u66ff\u5c3c<\/td>\n      		Ipilimumab
      \n\u4f0a\u5339\u5355\u6297<\/td>\n      		Ponatinib
      \n\u666e\u7eb3\u66ff\u5c3c<\/td>\n      		Vorinostat
      \n\u4f0f\u7acb\u8bfa\u4ed6<\/td>\n      		Cetuximab
      \n\u897f\u59a5\u6614\u5355\u6297<\/td>\n      		Ixazomib<\/td>\nRamucirumab
      \n\u96f7\u83ab\u82a6\u5355\u6297<\/td>\n      		Apatinib
      \n\u963f\u5e15\u66ff\u5c3c<\/td>\n<\/tr>\n
      Cobimetinib
      \n\u5361\u6bd4\u66ff\u5c3c<\/td>\n      		Lapatinib
      \n\u62c9\u5e15\u66ff\u5c3c<\/td>\n      		Regorafenib
      \n\u745e\u6208\u975e\u5c3c<\/td>\n      		Abiraterone<\/p>\n

      \u963f\u6bd4\u7279\u9f99<\/td>\n

      		Crizotinib
      \n\u514b\u5511\u66ff\u5c3c<\/td>\n      		Lenvatinib
      \n\u4e50\u4f10\u66ff\u5c3c<\/td>\n      		Rituximab
      \n\u5229\u59a5\u6614\u5355\u6297<\/td>\n      		Sirolimus<\/p>\n

      \u897f\u7f57\u83ab\u53f8<\/td>\n<\/tr>\n

      Rapamycin<\/p>\n

      \u96f7\u5e15\u9709\u7d20<\/td>\n

      		\u57c3\u514b\u66ff\u5c3c<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      \u88683 \u8986\u76d6\u7684\u5316\u7597\u836f\u7269<\/strong><\/p>\n\n\n\n\n\n
      \u5965\u6c99\u5229\u94c2(oxaliplatin)<\/td>\n\u5409\u897f\u4ed6\u6ee8(gemcitabine)<\/td>\n\u591a\u67d4\u6bd4\u661f(oxorubicin)<\/td>\n\u7532\u6c28\u8776<\/p>\n

      \u5464(methotrexate)<\/td>\n

      		\u8868\u67d4\u6bd4\u661f<\/p>\n

      (cepirubicin)<\/td>\n

      		\u5361\u57f9\u4ed6\u6ee8(capecitabine)<\/td>\n\u73af\u78f7\u9170\u80fa(cyclophosphamide)<\/td>\n\u4ed6\u83ab\u6614\u82ac<\/p>\n

      (tamoxifen)<\/td>\n<\/tr>\n

      \u5361\u94c2<\/p>\n

      (carboplatin)<\/td>\n

      		\u70f7\u5316\u5242<\/p>\n

      (Alkylating Agents)<\/td>\n

      		\u987a\u94c2<\/p>\n

      (cisplatin)<\/td>\n

      		\u4f0a\u7acb\u66ff\u5eb7(irinotecan)<\/td>\n\u5965\u6c99\u5229\u94c2<\/p>\n

      (oxaliplatin)<\/td>\n

      		\u4f9d\u6258\u6cca\u82f7(etoposide)<\/td>\n\u94c2\u7c7b\u5316\u5408\u5316\u5408\u7269<\/p>\n

      (Platinum compounds)<\/td>\n

      		\u7d2b\u6749\u9187<\/p>\n

      (paclitaxel)<\/td>\n<\/tr>\n

      \u591a\u67d4\u6bd4\u661f<\/p>\n

      (oxorubicin)<\/td>\n

      		\u5627\u5576\u7c7b\u4f3c\u7269<\/td>\n\u591a\u70ef\u7d2b\u6749\u9187(docetaxel)<\/td>\n\u5583\u6c1f\u5576<\/p>\n

      (tegafur)<\/td>\n

      		\u84bd\u73af\u7c7b\u836f\u7269<\/p>\n

      (Anthracyclines)<\/td>\n

      		\u6c1f\u5c3f\u5627\u5576\u3001\u4e9a\u53f6\u9178\u3001\u5965\u6c99\u5229\u94c2<\/p>\n

      (fluorouracil\u3001leucovorin\u3001oxaliplatin)<\/td>\n

      		\u957f\u6625\u65b0\u78b1<\/p>\n

      (Vincristine)<\/td>\n

      		<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

      \u80bf\u7624\u7cbe\u51c6\u533b\u5b66\u5927\u6570\u636e\u6280\u672f \u7275\u5934\u5355\u4f4d:\u4e2d\u79d1\u9662\u8ba1\u7b97\u6280\u672f\u7814\u7a76\u6240 \u4e2d\u79d1\u9662\u8ba1\u7b97\u6280\u672f\u7814\u7a76\u6240\u5728\u4f53\u7cfb\u7ed3\u6784\u3001\u5927\u6570\u636e\u3001\u4e91\u8ba1\u7b97\u3001\u4eba\u5de5\u667a […]<\/p>\n","protected":false},"author":2,"featured_media":1768,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[46],"tags":[],"_links":{"self":[{"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/posts\/1838"}],"collection":[{"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1838"}],"version-history":[{"count":4,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/posts\/1838\/revisions"}],"predecessor-version":[{"id":1973,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/posts\/1838\/revisions\/1973"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=\/wp\/v2\/media\/1768"}],"wp:attachment":[{"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1838"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/112.123.118.11:9997\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}